Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) will host a virtual 2026 Annual Meeting of Shareholders on Tuesday, January 27, 2026 at 1:00 p.m. ET. Shareholders of record as of the close of business on December 8, 2025, or their duly authorized proxies, can attend, participate, vote, and ask questions by visiting https://meetnow.global/MFT7Y46. Guests may join in listen-only mode without a control number. A replay of the webcast will be available shortly after the meeting at investors.bd.com for approximately one year from the meeting date.
BD (NYSE: BDX) announced the first prophylactic use of Phasix™ Mesh in Greece following its expanded CE-marked prophylactic indication in Europe, with the procedure performed at George Papanikolaou General Hospital in Thessaloniki.
The company reported the multicenter randomized PREVENT trial is >85% enrolled and is projected to complete enrollment in 2026, with results intended to support a U.S. PMA submission for incisional hernia prevention. Phasix launched three new sizes in 2025 and is registered in the U.K. Phasix is not indicated for hernia prevention in the United States.
BD (NYSE:BDX) announced a strategic collaboration with the Institute for Immunology and Immune Health at the University of Pennsylvania to develop and validate a high-parameter flow cytometry panel and support a planned 1,000-patient immune profiling study expected to start this summer.
The project will use the BD FACSDiscover A8 Cell Analyzer, BD Rhapsody system, BD reagents, software and informatics; BD will manage reagents, instrumentation and spectral data algorithms while Penn will serve as scientific and clinical leads. The panel aims to measure 30+ cellular characteristics, including phosphorylation markers, and the team intends to publish a peer-reviewed manuscript.
BD (NYSE: BDX) on Dec 15, 2025 announced IVDR certification in Europe for two VIASURE assays developed by Certest Biotec for the BD MAX™ System. The certified assays are the VIASURE Respiratory Virus Extended Mix (detects SARS-CoV-2, flu A/B, RSV, parainfluenza, human coronavirus, metapneumovirus, adenovirus from one nasopharyngeal swab) and the VIASURE HSV-1, HSV-2 & Treponema pallidum assay (detects HSV-1, HSV-2 and Treponema pallidum from anogenital and oral lesion swabs).
The announcement expands BD MAX molecular respiratory and STI testing options in Europe; the BD MAX System runs up to 24 samples per run, automates extraction/amplification/detection, and delivers results in ~three hours with <1 minute hands-on time per sample.
BD (NYSE: BDX) and ChemoGLO announced a strategic collaboration to expand hazardous drug contamination testing for health care facilities and laboratories.
The partnership pairs the BD HD Check System — providing qualitative, point-of-care results in 10 minutes — with ChemoGLO's LC-MS/MS quantitative analysis, which delivers an expanded hazardous‑drug panel report within 3–5 days after sample receipt. The workflow uses BD HD Check collection kits for safe shipping to ChemoGLO for follow-up testing.
The combined approach aims to help facilities quickly identify contamination and gain deeper quantitative insights to better protect health care workers. BD and ChemoGLO will be at the ASHP Midyear Clinical Meeting in Las Vegas, Dec 6–10, 2025 (BD Booth 1017; ChemoGLO Booth 1873).
BD (NYSE:BDX) announced on Dec 3, 2025 new three- and four-laser configurations of the BD FACSDiscover A8 Cell Analyzer, expanding access to spectral and real-time cell imaging for academia, pharma and biotech.
Key features include BD SpectralFX (analyzes up to 50+ cell characteristics), BD CellView Image for high-speed spatial/morphological imaging, optional free trials and later software upgrades, and compatibility with BD sorters and new near-infrared fluorochromes. Instruments are available to order with flexible financing options.
BD (NYSE: BDX) announced the European launch of the BD Surgiphor Surgical Wound Irrigation System on November 24, 2025. The device received CE approval and is now available in select European countries. Surgiphor is a sterile, pre-mixed, ready-to-use irrigation solution that uses a trusted antiseptic preservative to help loosen and remove debris and reduce bacterial load in surgical wounds. BD says the product is designed to simplify wound irrigation, reduce preparation time, and support evidence-based practices to help lower the risk of surgical site infections and improve surgical safety.
Availability is limited to select countries in Europe; healthcare providers should contact BD sales representatives for regional access and product details.
BD (NYSE:BDX) announced a pharmacy automation partnership with Henry Ford Health on Sept. 22, 2025 to develop a hospital and community pharmacy robotic solution using the BD Rowa Vmax.
The collaboration will pilot 24/7 prescription pickup, automated high-capacity storage and refrigerated handling, real-time prescription tracking, and modular scalability to improve pharmacy staff efficiency and ensure patients leave with medications in hand at discharge or clinic visits.
BD (NYSE: BDX) announced the appointment of Robert Huffines and Jacqueline Wright to its board of directors, effective Dec. 1, 2025. The company said the additions add expertise in health care, technology, digital transformation, artificial intelligence, finance and capital markets as BD advances its strategy to be a scaled pure‑play medical technology company. BD added three new independent directors in 2025, reflecting ongoing board refreshment. Bios note Huffines' 30+ years in healthcare investment banking and board service, and Wright's 30+ years in technology and digital transformation at McKinsey and Microsoft.
BD (NYSE: BDX) announced that the CE-marked BD Onclarity HPV Assay for the BD COR and BD Viper LT systems received WHO prequalification on November 17, 2025, enabling wider use in low- and middle-income countries.
The assay detects 14 high-risk HPV types with extended genotyping (six individual types plus three genotype groups), supports self-collection including at-home where CE is recognized, and targets improved risk stratification and follow-up. The BD COR offers ~1,650-test capacity and up to 1,000 results in 24 hours; BD Viper LT provides compact, decentralized molecular testing.